Gener­ic and brand-name drug­mak­ers have been di­vid­ed for decades over the use of “skin­ny la­bels” to bring low­er-cost drugs to mar­ket.

Now, the Supreme Court is tak­ing up the is­sue.

It’s wad­ing in­to a case that could have broad­er im­pli­ca­tions on how drug­mak­ers launch gener­ics and nav­i­gate le­gal risks. The high court turned down a sim­i­lar skin­ny la­bel dis­pute three years ago, and le­gal ex­perts say it was just a mat­ter of time be­fore it ad­dressed the is­sue.

“Some­times it's a mat­ter of just hav­ing an is­sue per­co­late a few times up to them,” said Chad Land­mon, an in­tel­lec­tu­al prop­er­ty lawyer with Polsinel­li. “They're see­ing it for an­oth­er time, and see­ing that it's a con­tin­ued is­sue.”

The top five bio­phar­ma com­pa­ny spenders on con­gres­sion­al lob­by­ing spent slight­ly less in Wash­ing­ton in the fi­nal quar­ter of 2025 than they did in the pre­vi­ous quar­ter, the lat­est Sen­ate dis­clo­sures show.

Pfiz­er and John­son & John­son both spent $1 mil­lion less on lob­by­ing in Q4 than Q3 2025, al­though all five com­pa­nies' Q4 num­bers were gen­er­al­ly aligned with what they shelled out in the year ear­li­er, ac­cord­ing to the Sen­ate data­base.

As far as spe­cif­ic is­sues draw­ing at­ten­tion, No­var­tis point­ed to NIH fund­ing, which saw a slight boost in the most re­cent gov­ern­ment fund­ing bill be­fore Con­gress, "most fa­vored na­tion" pric­ing and PBM re­forms, which were added to the fund­ing bill too.

Am­gen and Pfiz­er sim­i­lar­ly called out PBM re­forms as among their top lob­by­ing is­sues. Pfiz­er al­so point­ed to vac­cine pol­i­cy and CDC changes as top pri­or­i­ties.

Shang­hai-based Hua Med­i­cine wants to cap­ture a greater share of the glob­al di­a­betes mar­ket with a dif­fer­ent ap­proach from pop­u­lar GLP-1 med­i­cines.

Many new­er di­a­betes drugs mim­ic gut hor­mones to reg­u­late glu­cose. Hua's drug for type 2 di­a­betes, ap­proved in Chi­na un­der the name Dorza­gli­atin, does not mim­ic hor­mones but in­stead mod­u­lates the body’s bio­chem­i­cal ma­chin­ery. It en­hances the ac­tiv­i­ty of glu­cok­i­nase, an en­zyme that has a broad role in con­trol­ling blood sug­ar.

Hua is plan­ning to ex­pand Dorza­gli­atin be­yond main­land Chi­na and in­to Hong Kong, Macau and South­east Asia. It's al­so test­ing a next-gen­er­a­tion ver­sion that's de­signed to pro­vide more sta­ble glu­cose con­trol, tar­get­ing glob­al ex­pan­sion.

"Hua’s strat­e­gy is to demon­strate the broad ben­e­fits of ad­dress­ing the root cause of type 2 di­a­betes," chief strat­e­gy of­fi­cer George Lin told End­points News dur­ing the JP Mor­gan Health­care Con­fer­ence.

Janux Ther­a­peu­tics has found a new part­ner.

The San Diego-based biotech is team­ing up with Bris­tol My­ers Squibb on a sol­id tu­mor pro­gram, but the tar­get is not yet dis­closed. Bris­tol My­ers will pay $50 mil­lion in up­front and near-term cash, and could be on the hook for about $800 mil­lion more in mile­stones.

The pro­gram in­volved in the deal is still pre­clin­i­cal. Janux will han­dle all de­vel­op­ment up to the IND stage, af­ter which Bris­tol My­ers will take the lead. Janux, how­ev­er, will al­so re­main “ac­tive­ly in­volved” through Phase 1 stud­ies, ac­cord­ing to a Thurs­day re­lease.

The deal comes a few weeks af­ter a dis­ap­point­ing tri­al read­out from Janux. In De­cem­ber, the biotech re­port­ed that its lead pro­gram, JANX007, saw its re­sponse rate drop as more pa­tients re­ceived the drug. JANX007 is be­ing test­ed for an ad­vanced form of prostate can­cer.

Cor­cept Ther­a­peu­tics said its ex­per­i­men­tal drug cut the risk of death by 35% for pa­tients with a chal­leng­ing form of ovar­i­an can­cer when added on top of chemother­a­py, notch­ing an im­por­tant win af­ter the Cal­i­for­nia biotech faced an FDA re­jec­tion of its drug in a dif­fer­ent dis­ease.

In re­sults an­nounced Thurs­day morn­ing, Cor­cept re­port­ed that plat­inum-re­sis­tant ovar­i­an can­cer pa­tients who re­ceived its drug rela­co­ri­lant on top of chemother­a­py lived for a me­di­an of 16 months. That’s com­pared to 11.9 months for pa­tients who re­ceived chemother­a­py alone as part of the Phase 3 ROSEL­LA study. The dif­fer­ence was sta­tis­ti­cal­ly sig­nif­i­cant, trans­lat­ing to a p-val­ue of 0.0004 and meet­ing its sec­ond pri­ma­ry end­point in the tri­al.

Since its 2019 found­ing, Corx­el Phar­